Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedPAC Considering Two Options For Reinstating Medicare Least Costly Alternative Policy For Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Both proposals involve legislation that would authorize Medicare Part B to pay for drugs based on the price of the lowest-cost alternative.

You may also be interested in...



MedPAC Seeks Stakeholder Input On Medicare “Least Costly Alternative” Policy

Comments by members of the Medicare Payment Advisory Commission at a recent meeting suggest an opportunity for pharmaceutical industry stakeholders to help frame the discussion of Medicare value-based payment approaches for Part B drugs.

OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings

Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.

OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings

Analysis of money spent on the treatments for wet age-related macular degeneration offers an argument for least costly alternative policy as a way of cutting health care spending.

Related Content

Topics

UsernamePublicRestriction

Register

PS071404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel